As US virus cases grow, so does the case for ‘big government’

Weekly Market Compass: Another injection of fiscal stimulus may be on the horizon

I caught a bit of the James Bond movie “Casino Royale” on TV over the weekend. I couldn’t help but fixate on something that I never thought of before – the government expenditures required to bankroll 007’s missions. After all, this guy isn’t independently wealthy. Imagine if British taxpayers really had to fund the costly gadgets, the pricey watches, the luxury SUV, the expensive hotel accommodations — even a generous gambling allowance. If James Bond were a real person – and especially if he were American – wouldn’t there be vigorous protests against him, vilifying him as the poster boy for “big government”? Perhaps. But there’s one important thing to keep in mind — his missions often solved crises, and that has a way of making most people fans. In real life, just like in these movies, it often takes big government to solve big problems.

For evidence of that, look no further than the Global Financial Crisis and the historic federal intervention that was designed to rescue the economy. Even officials who were typically against big government understood that the magnitude of the challenge required a powerful response. I can’t help but recall a famous quote from then-Federal Reserve Chair Ben Bernanke, “There are no atheists in foxholes and no ideologues in financial crises.”1

While today’s crisis is first and foremost a health crisis, there are very significant financial ramifications. And so I wouldn’t expect to see many complaints about another injection of fiscal stimulus — especially in the United States, which has been unable to effectively contain the spread of COVID-19 as have other major economies such as the EU, the UK and China. More help is clearly needed, despite improving economic data.

As I covered in my commentary last week, the US is in a very different situation than China, which has successfully controlled the virus. Last week, the US set a new one-day record of 75,000 new coronavirus cases.2 Rising US infections could result in greater stringency in protocol (i.e., rollbacks of re-openings) as well as self-quarantining by households, both of which threaten to stall the very recent recovery in US economic activity. This is different from China, where second-quarter gross domestic product showed that an economic recovery is underway: The virus was controlled and lockdown measures were rolled back. In addition, China stepped up fiscal stimulus. And because China was able to successfully stamp out the virus, this suggests that China is well-equipped to manage any resurgence — including the very feared possibility of a second wave later this year.

A US stimulus package may be on the way

More assistance does appear to be on the way for the US. There is growing consensus that the next fiscal stimulus package may be north of $1 trillion as fiscal hawks in the US disappear like proverbial atheists in foxholes.3 All of this is helped, of course, by the fact that it is an election year. This package is likely to include extended job benefits (albeit at a lower cap), new checks to lower-income households, and funding for state and local governments. (One caveat: This possible stimulus package is not a fait accompli given that President Donald Trump has threatened to veto it if it doesn’t include a payroll tax cut.)

While this package wouldn’t be nearly as generous as the $3 trillion HEROES package passed by the US House of Representatives back in May, I believe it is movement in the right direction. I expect the US to fall into a pattern where, every month or two, Congress must pass a new stimulus package to keep the economy going — especially if “the curve” is not successfully bent.

Vaccine trials show progress, while the evidence for wearing masks grows

There has been some good news on the health front as well. Last week a preliminary report published in the New England Journal of Medicine indicated that Phase One clinical trials of a vaccine developed by Moderna created antibodies in all participants in the study.4 Those who received two doses of the vaccine developed levels of neutralizing antibody activity that were actually higher than the average levels observed in convalescent serum (i.e., serum taken from people who recovered from confirmed novel coronavirus). Now it is unclear if this creates longer-term immunity, but the participants in the study will continue to be monitored for the presence of antibodies, so we will learn more as time goes on.

Just as important — but receiving no notice from Wall Street – was information released last week by the Centers for Disease Control and Prevention regarding two hairstylists in Springfield, Missouri.5 These hairstylists were infected with COVID-19 and were symptomatic, making it easier for them to transmit the virus, but continued to provide haircuts to customers — 139 in total — in May of this year. And yet no symptomatic secondary cases were reported as a result of this contact; of those 67 clients who volunteered to be tested for COVID-19, all tested negative.  One important point to make: The hairstylists and the clients all wore face masks during the haircuts.

Looking ahead

To me, the message is clear: Wearing face masks can help us resume economic activity and potentially avoid reinstating the type of stringent measures that ground business activity to a near-halt earlier in the year. In my view, this is a simple step that can promote both public health and the health of US stocks. Think of it as something akin to a fabric vaccine.

Looking ahead, I believe the stock market would benefit from news of a stimulus package coming to fruition — even if it is only a portion of what the HEROES Act would have been. In times like this, despite a massive and rising budget deficit for the US, I believe big government is likely to be good news for the stock market. However, I must add that I do worry about the renewed risk of rising tensions between the US and China. Last week Attorney General William Barr was very provocative in a speech he gave in Michigan, accusing China of launching an “economic blitzkrieg” against the United States.6 Also last week, President Trump signed an executive order imposing sanctions on Chinese officials and removing Hong Kong from its status as a favored trading partner.7  Some retaliation could come from China, which could undermine confidence in global stocks. We will want to follow this situation closely.

1 Source: The New York Times, “A Professor and a Banker Bury Old Dogma on Markets,” Sept. 20, 2008

2 Source: Centers for Disease Control and Prevention

3 Source: CNBC: “Nancy Pelosi says coronavirus aid bill will cost at least $1.3 trillion, but ‘that’s not enough,’” July 16, 2020

4 Source: New England Journal of Medicine, “An mRNA Vaccine against SARS-CoV-2 — Preliminary Report,” July 14, 2020

5 Source: Centers for Disease Control and Prevention, “Absence of Apparent Transmission of SARS-CoV-2 from Two Stylists After Exposure at a Hair Salon with a Universal Face Covering Policy — Springfield, Missouri, May 2020,” July 17, 2020

6 Source: CNBC, “AG Barr slams U.S. tech companies for becoming ‘pawns of Chinese influence,’” July 16, 2020

7 Source: NBC News, “Trump signs Hong Kong sanctions bill, announces executive order in escalation with China,” July 14, 2020

Important information

Blog header image: Tempura / Getty

The opinions referenced above are those of the author as of July 20, 2020. These comments should not be construed as recommendations, but as an illustration of broader themes. Forward-looking statements are not guarantees of future results. They involve risks, uncertainties and assumptions; there can be no assurance that actual results will not differ materially from expectations.

Kristina Hooper is Chief Global Market Strategist at Invesco. In this role, she leads Invesco’s Global Market Strategy (GMS) Office, which has strategists on-the-ground in North America, Europe and Asia. Ms. Hooper and her team formulate macro views of the markets and economy, examine the investment implications of those views, and share their insights with clients and the media around the world.

Prior to joining Invesco, Ms. Hooper was the US investment strategist at Allianz Global Investors. Prior to Allianz, she held positions at PIMCO Funds, UBS (formerly PaineWebber) and MetLife. She has regularly been quoted in The Wall Street Journal, Financial Times, The New York Times, Reuters and other financial news publications. She was featured on the cover of the January 2015 issue of Kiplinger’s magazine, and has appeared regularly on CNBC, Bloomberg TV. She joined the investment industry in 1995.

Ms. Hooper earned a BA degree, cum laude, from Wellesley College; a J.D. from Pace University School of Law, where she was a Trustees’ Merit Scholar; an MBA in finance from New York University, Leonard N. Stern School of Business, where she was a teaching fellow in macroeconomics and organizational behavior; and a master’s degree from the Cornell University School of Industrial and Labor Relations, where she focused on labor economics. Ms. Hooper is a Certified Financial Planner® (CFP), Chartered Alternative Investment Analyst (CAIA), Certified Investment Management Analyst® (CIMA) and Chartered Financial Consultant® (ChFC) professional. She previously served on the board of trustees of the Foundation for Financial Planning, which is the pro bono arm of the financial planning industry.


More in Market & Economic
Expectations diverge for economic recovery in the US and China

Last week, we saw increases in both the Chinese and US stock markets. But that’s where the similarities end — there is currently a meaningful...